Context: Evidence-based guidelines for active surveillance (AS), a treatment option for men 26 with low-risk prostate cancer, recommend regular follow-up at periodic intervals to monitor 27 disease progression. However, gaps in monitoring can lead to delayed detection of cancer 28
Introduction 52
Prostate cancer is the most common cancer in men in the United States, and second 53 most common internationally. 1,2 Most prostate cancers are low-risk and slow growing; 54 however, a subset can progress to more lethal disease. 3 Active surveillance (AS) is the 55 recommended standard of care for low-and some intermediate-risk prostate cancers that have 56 little risk of progression. 4 AS defers active treatment (e.g., surgery or radiation) with close 57 monitoring and leads to active treatment if the cancer progresses (e.g., low grade disease 58 becomes higher grade disease), the cancer is reclassified (e.g., detected a previously 59 undetected cancer of higher grade on confirmatory or surveillance biopsy), or the patient 60 decides to pursue active treatment. AS also provides the opportunity to maintain men's quality 61 of life without the potential adverse effects of treatment. 5 
62
AS eligibility criteria and monitoring guidelines vary widely by institution, but generally 63 recommend regular monitoring for disease progression that includes prostate-specific antigen 64 (PSA) tests, digital rectal exams (DRE), and repeat prostate biopsies at periodic intervals. 6 65 However, the extent of patient adherence to AS protocols is unclear. Little is known about 66 which populations or settings are more vulnerable to monitoring gaps, or multi-level factors 67 associated with non-adherence or loss to follow-up (LTFU). 68
In this systematic review, we sought to identify if and how real-world observational 69 studies tracked and reported adherence to AS protocols when evaluating outcomes of prostate 70 cancer patients on AS. Specifically, we aimed to assess whether or not such studies reported 71 patient adherence to AS protocols (e.g., PSA tests, DREs, repeat biopsies, and duration and 72 frequency of monitoring received). When studies reported adherence, we sought to understand 73 how investigators define and measure adherence, as well as the range of adherence rates. 74
75

Evidence Acquisition 76
Our review was guided by the PRISMA statement. 7 We conducted a systematic literature 77 search (PROSPERO #CRD42016051128) on March 8, 2018 and updated on March 22, 2019 in 78
PubMed, Embase, and CENTRAL. We created our search strategy in collaboration with a clinical 79 librarian (JBW) using text words and controlled vocabulary, including MeSH and Emtree terms 80 (e.g., "active surveillance" and "Prostatic Neoplasms" [Mesh] ). Appendix A details the complete 81 search strategy. 82
Study eligibility criteria included: 1) focus on AS for prostate cancer; 2) real-world 83 observational study reporting actual patient care (e.g., a retrospective medical chart review); 3) 84 followed a predetermined evidence-based AS clinical eligibility criteria (e.g., PSA level, Gleason 85 score, stage, number of positive cores, etc.) and an AS monitoring protocol (e.g., National 86
Comprehensive Cancer Network [NCCN] guidelines -PSA every 6 months, annual DRE and 87 biopsy); 4 and 4) reported outcome data (e.g., survival rates, movement to active treatment, or 88 LTFU). We excluded non-English studies, studies that evaluated outdated AS protocols, as well 89 as studies that solely reported on active treatment patients. Clinical trials, interventional 90 studies, efficacy trials (e.g., study cohorts with a study protocol), or studies comparing different 91 treatment modalities to test protocols or treatment effectiveness were also excluded. 92
Two reviewers (GK, SL) independently screened titles and abstracts to determine 93 relevancy and eligibility, and completed full text reviews. A third reviewer (US, BB, or NP) 94 reconciled discrepancies. We collected several data elements on adherence and outcomes 95 (Table 1) . We categorized studies as reporting adherence if they explicitly included a measure 96 with the term "adherence" or "compliance". We considered the adherence/compliance 97 definition time-bound if it included the timeliness of monitoring (e.g. patient adherent if repeat 98 biopsy completed within six months of a designated date). We considered the definition binary 99 if it assessed adherence, but was not time-bound (e.g. testing received versus not). We 100 tabulated adherence definitions and results, when provided. We used the Strengthening the 101
Reporting of Observational Studies in Epidemiology (STROBE) checklist to assess study quality. 8 102
103
Evidence Synthesis 104
We screened 6,118 articles' titles and abstracts and reviewed the full text of 267 105 articles. After applying our inclusion and exclusion criteria, we included 45 studies (Figure 1) , 106 and classified them into four mutually exclusive groups (Figure 2) . 107
Study characteristics 108
After removing participant sub-groups who did not meet our eligibility criteria (e.g., 109
enrolled in a randomized controlled trial or who did not undergo AS), we ultimately included a 110 total of 29,143 participants (range: 34 -5,302) from 45 studies. The earliest enrollment in an AS 111 program began in 1990, 9,10 culminating as late as 2017. 11 112
Eligibility criteria into AS programs varied across studies; however, most studies 113 restricted inclusion by diagnostic criteria -e.g., Gleason score ≤ 6, PSA ≤ 10 ng/ml, ≤ 33% 114 positive biopsy cores, and ≤ 50% involvement in a single core. Some studies stated they 115 included select men with higher risk features, such as those with a strong preference for AS. 9,12-116 19 A few studies considered patients' cognitive capacity to understand AS programs as well as 117 their ability to attend follow-up visits. 20,21 Eligibility criteria also changed over time in certain 118 long-term studies, reflecting a general trend in the evolution of AS protocols. 9,22-26 119
Most studies reported follow-up time on AS, however the measure varied based on 120 when investigators determined follow-up began (e.g. upon diagnosis or agreement to enroll 121 into an AS program) and ended (e.g. upon study completion, movement to active treatment, or 122 other censorship). 9,10,12-19,21-24,27-44 Median follow-up time ranged from 16.9 months 33 to 6.7 123 years. 31,33 124
Patient characteristics 125
All 45 studies reported patient age and clinical characteristics -such as Gleason score, 126 PSA, number of positive biopsy cores, risk classification, and clinical stage. Fourteen studies 127 reported patient race/ethnicity. 9, 11, 15, 18, 19, 22, 23, [35] [36] [37] [38] [39] [40] 45 Four of these publications specifically 128 focused on studying racial/ethnic minorities. 22, 23, 35, 37 Two studies reported patients' marital 129 status. 9, 19 Two studies also reported tobacco use history; 9,23 however, only one also reported 130 history of substance abuse, mental illness, homelessness, and primary language. 23 
131
AS protocols 132
Follow-up protocols varied across studies, using strict or modified NCCN, 15 proportion of PSA tests and biopsies performed compared to the total that should have been 166 completed. 30 We summarize these results in Table 3 . 167
Undefined measures of adherence 168
We included 25 studies that did not explicitly define adherence, but either (1) The remaining 13 studies did not define adherence but reported a measure that we 179 considered representative of adherence. 9,10,14,16,24,26,36,38,39,43,48,50,53 For example, some studies 180 reported the median number of biopsies received 10,14,38 and the number of men who received a 181 follow-up test. 9,14,16,24,26,36,38,48,50,53 However, these measures lacked a corresponding time 182 frame, such that it is unclear if the tracked biopsies occurred within one year, two, or 183 throughout the entire study period. Other studies lacked key information, such as the total 184 number of patients on AS to compare to the number that received follow-up testing. 26,50,53 185
Lost to Follow-Up (LTFU) 186
Twenty-three studies provided information on patients LTFU. Rates of LTFU vary from 187 none 52 to 19.5% 30 , however this measure was not consistently defined across studies making 188 comparison infeasible. We saw various approaches to defining whether or not a patient was 189 LTFU. Hefermehl et al considered patients LTFU after no response or information about the 190 patient more than 12 months after the last scheduled appointment. 30 Osterberg et al, 191
alternatively, considered 31% of patients LTFU after failing to reach them after three attempted 192 phone calls, until querying a cross-institutional database that indicated only 17.3% of patients 193 were truly LTFU. 23 In addition, some studies excluded patients LTFU. 10,39,40,42 194
Ballas et al examined the association between the chance of being LTFU and 195 socioeconomic status (SES). 35 They found that the cumulative incidence of being LTFU at a 196 safety-net hospital was significantly higher (57% at 5 years) than at a comprehensive cancer 197 center (37% at 5 years), and that lower SES was associated with likelihood of being LTFU. 198
Study Quality and Potential Bias 199
According to the STROBE checklist, 8 the overall quality of studies included was high. African American men may have a higher risk of disease reclassification, as found in a recent 220 systematic review. 59 Additionally, men with intermediate-risk disease who can be safely 221 monitored on AS have more than a three times higher risk of metastasis at 15-year follow-222 up. 57,60 AS -including the extent to which it is followed -should be reported and studied to 223
further understand the quality of AS care, resources needed to ensure high-quality monitoring 224 (e.g., registries), and how protocols can be more widely implemented across diverse settings 225 and populations safely to prevent overtreatment without compromising quality of life and 226 survival. This involves understanding a range of constructs including adherence and various 227 implementation outcomes, which is critical to understanding the wider implementation and 228 dissemination of AS in clinical practice. 229
Most studies did not evaluate the potential impact of multi-level factors on adherence. 230
For example, only one study examined whether or not patients on AS experienced 231 homelessness or had a history of mental illness, 23 and only two studies detailed how clinics 232 performed monitoring or responded to patients' concerns surrounding AS (e.g. a dedicated 233 nurse conducted follow-up activities and supported patients experiencing anxiety). 16, 21 Prior 234 research indicates patient-, provider-, and system-level factors such as these may influence 235
adherence. [61] [62] [63] [64] [65] [66] For example, Kinsella et al identified multi-level barriers and facilitators to AS 236 adherence including cancer characteristics (e.g., lower PSA), patients' perceived benefits and 237 harms, social support (e.g., peer support, partner anxiety), receipt of useful information 238 communicated by providers, healthcare organization and practice (e.g., educational classes on 239 AS), and health policy factors (e.g., national guidelines). 64 We also recognize that adherence to 240 AS protocols may vary by patient preference (e.g., refuses repeat biopsy), physician practice 241 (e.g., tailors based on clinical and follow-up characteristics), health care system and country 242 (e.g., follow NCCN versus the American Urological Association [AUA] guidelines or others), 67 243 and the availability of multi-parametric magnetic resonance imaging. 68 Identifying barriers and 244 facilitators to AS adherence is crucial for successful long-term disease management that delays 245 or avoids unnecessary treatment until it is warranted, and can inform intervention 246
development. 247
As a framework to examine the interrelated components affecting high quality care, 248 including adherence, the Chronic Care Model is a promising model for improving management 249 of chronic conditions. 69 AS constitutes ongoing care for a chronic condition; as such, this 250 framework suggests looking to a health system situated within a community, in which 251 productive interactions between a prepared, proactive practice team and engaged and active Future studies should track and report variables relevant to follow-up care for and 267 adherence to AS protocols. First, studies should determine a definition of adherence to AS 268 protocols based on guideline-recommended time (e.g., every 6 months) or a pre-defined grace 269 period (e.g. within three months of recommended testing). Second, an adherence rate to 270 monitoring (e.g., completed PSA testing, annual biopsy and DRE, etc.) should be calculated, 271 along with the average time between monitoring. Third, studies should also report AS 272 outcomes, including number and rate patients moved to active treatment, whether due to 273 disease progression, reclassification, or patient preference. Lastly, studies should define and 274 assess LTFU, including associated factors (e.g., race, comorbidities), 73 
net settings can introduce unique barriers to implementing evidence-based recommendations 279 in prostate cancer care, particularly for AS. [74] [75] [76] Patient-centered and technology-enabled 280 solutions to measure and improve adherence must also be designed for and tested in settings 281 that disproportionately care for low-income and vulnerable populations, many of whom 282 already face barriers to accessing care. 283
While we report on studies that include both measures of adherence and compliance, it 284 is important to differentiate between the two terms, as recommended by the World Health 285
Organization. 77 The former connotes an active agreement between patient and provider: does 286 the patient adhere to an agreed-upon recommendation? The latter suggests a more passive 287 role of the patient: does the patient comply with a physician's orders? When discussing AS, the 288 success of which is dependent on the patient's agreement and understanding of follow-up care, 289 we believe that "adherence" better reflects the inherent shared decision-making paradigm. 290
There are limitations to this systematic review. First, since AS protocols differ across 291 settings, we could not compare adherence across studies. As a result, we decided to focus on 292 primary data analysis of real-world observational studies within single or multiple settings using 293 the same follow-up protocol, rather than secondary data analysis of cancer registries or 294 consortiums employing various protocols. We also limited our review to studies that had 295 predetermined evidence-based AS clinical eligibility criteria and monitoring protocols, which 296 excluded a few studies (e.g., those reporting on the MUSIC consortium). 73, 78 This was done to 297 capture studies that intended to follow patients who were clinically appropriate and monitored 298 based on a predetermined protocol (e.g., NCCN). We also included non-US studies and 299 recognize that differences in health care systems across countries have implications for 300 variations in access to and quality of care. However, we hope our review illustrates the need for 301 consistent definitions and reporting of adherence in order to move towards a standardized AS 302 protocol. Also, the causality between adherence to AS and patient outcomes is not well 303 understood due to the focus on short-term outcomes in the literature; however, successful 304 receipt of timely follow-up visits and testing should be treated as a necessary metric when 305 reporting AS outcomes. 61 306
To our knowledge, this is the first systematic review that assesses the extent adherence 307 to follow-up protocols is measured in real-world observational studies reporting outcomes of 308 men on AS. Due to the large number of men managed by AS, this work offers valuable 309 implications that may improve the delivery of care for prostate cancer patients on AS. In 310 addition, previous studies demonstrating differences in prognostic value and prostate cancer 311 specific mortality for men on AS by race and ethnicity indicate that it is imperative to 312 thoroughly understand factors associated with successful disease management, including 313 adherence, in order to move the needle towards recognizing and reducing disparities. 79,80 314
315
Conclusions 316
Adherence to evidence-based AS protocols is not uniformly reported or defined in the 317 scientific literature. As AS becomes a more common management strategy among men with 318 low-risk prostate cancer, our findings highlight the need for more research to: (1) establish 319 adherence definitions and measures relevant to AS; (2) include adherence as a quality 320 improvement measure for AS outcomes; and (3) track and identify multilevel factors associated 321 with adherence and LTFU. 
